Related Experiment Video
Updated: May 1, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Typical or atypical pneumonia and severe acute respiratory symptoms in PICU
Kam Lun Hon1, Agnes S Y Leung1, Kam Lau Cheung1
1Departments of Paediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong.
Background And Aims:
Mycoplasma pneumoniae (MP) is a common childhood pathogen associated with atypical pneumonia (AP). It is often a mild disease and seldom results in paediatric intensive care (PICU) admission. In 2003, World Health Organization (WHO) coined the word SARS (severe acute respiratory syndrome) in patients with severe acute respiratory symptoms (sars) for an outbreak of AP in Hong Kong due to a novel coronavirus. In 2012, another outbreak of coronavirus AP occurred in the Middle East. Confusing case definitions such as MERS (Middle East respiratory syndrome) and SARI (severe acute respiratory infections) were coined. This paper aims to present a case of MP with sars, ARDS, pneumonia and pleural effusion during the MERS epidemics, and review the incidence and mortality of severe AP with MP.
Methods:
We presented a case of MP with sars, acute respiratory distress syndrome (ARDS), pneumonia and pleural effusion during the MERS epidemics, and performed a literature review on the incidence and mortality of severe AP with MP requiring PICU care.
Results:
In early 2013, an 11-year-old girl presented with sars, ARDS (acute respiratory distress syndrome), right-sided pneumonia and pleural effusion. She was treated with multiple antibiotics. Streptococcus pneumoniae was not isolated in this girl with 'typical' pneumonia by symptomatology and chest radiography, but tracheal aspirate identified MP instead. The respiratory equations are computed with PaO2 /FiO2 consistent with severe lung injury. Literature on the incidence and mortality of severe AP with MP requiring PICU care is reviewed. Six, 165 and 293 articles were found when PubMed (a service of the U.S. National Library of Medicine) was searched for the terms 'mycoplasma' and 'ICU', 'mycoplasma' and 'mortality', and 'mycoplasma' and 'severe'. Mortality and PICU admission associated with MP is general low and rarely reported. Experimental and clinical studies have suggested that the pathogenesis of lung injuries in MP infection is associated with a cell-mediated immune reaction, and high responsiveness to corticosteroid therapy has been reported especially for severe disease. Management of severe mycoplasma infection in the PICU includes general cardiopulmonary support and specific antimicrobial treatment. Macrolide resistance genotypes have been detected.
Conclusion:
We urge health organizations to refrain from the temptation of coining unnecessary new terminology to describe essentially the same conditions each and every time when outbreaks of AP occur.
Insights
Mycoplasma pneumoniae (MP) can cause severe atypical pneumonia (AP) requiring pediatric intensive care (PICU). While rare, severe MP cases highlight the need for clear diagnostic criteria and management strategies for pediatric respiratory infections.
Area of Science:
- Pediatric Infectious Diseases
- Respiratory Medicine
- Critical Care Medicine
Background:
- Mycoplasma pneumoniae (MP) is a common childhood pathogen causing atypical pneumonia (AP).
- Severe presentations of AP, particularly those requiring pediatric intensive care (PICU), are uncommon.
- Outbreaks of severe respiratory illnesses have led to the creation of various, sometimes confusing, terminologies like SARS, MERS, and SARI.
Observation:
- A case of an 11-year-old girl with severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), pneumonia, and pleural effusion is presented.
- MP was identified as the causative agent, despite initial presentation mimicking typical pneumonia.
- The patient's respiratory status indicated severe lung injury, necessitating PICU admission.
Findings:
- Literature review indicates that severe AP requiring PICU admission due to MP is rarely reported, with generally low mortality.
- The pathogenesis of lung injury in MP infection involves a cell-mediated immune response.
- Severe MP cases may respond well to corticosteroid therapy, alongside general cardiopulmonary support and antimicrobial treatment.
Implications:
- This case underscores the importance of considering MP in severe pediatric pneumonia, even with atypical presentations.
- Standardized diagnostic approaches and clear terminology are crucial for managing severe respiratory infections.
- Further research into MP pathogenesis and treatment, including macrolide resistance, is warranted for optimizing patient outcomes.
Related Concept Videos
Atypical Pneumonia
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Pneumonia II: Pathophysiology
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
